Ronald E. Bruehlman Joins GoodRx Board of Directors
GoodRx Holdings announced the appointment of Ronald E. Bruehlman to its Board of Directors, effective November 8, 2024. Bruehlman, currently the CFO of IQVIA, brings 39 years of finance experience in healthcare services, industrial, and petroleum industries. He will serve as chairperson of the Board's Audit and Risk Committee, replacing Julie Bradley. Previously, Bruehlman served as CFO of IMS Health and held senior finance leadership roles at United Technologies for 23 years. The appointment aims to strengthen GoodRx's financial strategy and risk assessment capabilities as the company focuses on sustainable and profitable revenue growth.
GoodRx Holdings ha annunciato la nomina di Ronald E. Bruehlman nel suo Consiglio di Amministrazione, con effetto dall'8 novembre 2024. Bruehlman, attualmente CFO di IQVIA, porta con sé 39 anni di esperienza finanziaria nei settori dei servizi sanitari, industriali e petroliferi. Assumerà il ruolo di presidente del Comitato di Audit e Rischi del Consiglio, sostituendo Julie Bradley. In precedenza, Bruehlman è stato CFO di IMS Health e ha ricoperto ruoli di leadership finanziaria senior in United Technologies per 23 anni. Questa nomina mira a rafforzare la strategia finanziaria di GoodRx e le capacità di valutazione del rischio mentre l'azienda si concentra sulla crescita dei ricavi sostenibile e redditizia.
GoodRx Holdings anunció el nombramiento de Ronald E. Bruehlman en su Junta Directiva, con efecto desde el 8 de noviembre de 2024. Bruehlman, actual CFO de IQVIA, aporta 39 años de experiencia financiera en los sectores de servicios de salud, industrial y petrolero. Asumirá el cargo de presidente del Comité de Auditoría y Riesgo de la Junta, reemplazando a Julie Bradley. Anteriormente, Bruehlman fue CFO de IMS Health y ocupó puestos de liderazgo financiero durante 23 años en United Technologies. Este nombramiento tiene como objetivo fortalecer la estrategia financiera de GoodRx y las capacidades de evaluación de riesgos mientras la empresa se centra en un crecimiento sostenible y rentable de ingresos.
GoodRx Holdings는 Ronald E. Bruehlman을 이사회의 사보로 임명했다고 발표했으며, 이는 2024년 11월 8일부터 시행됩니다. 현재 IQVIA의 CFO인 Bruehlman은 헬스케어 서비스, 산업 및 석유 산업에서 39년의 금융 경험을 가지고 있습니다. 그는 Julie Bradley를 대신하여 이사회의 감사 및 위험 관리 위원회의 의장을 맡게 됩니다. 이전에 Bruehlman은 IMS Health의 CFO로 활동하였고, 23년 동안 United Technologies에서 선임 재무 리더십 역할을 수행했습니다. 이번 임명은 GoodRx의 금융 전략과 위험 평가 능력을 강화하기 위한 것으로, 회사는 지속 가능하고 수익성 있는 수익 성장에 집중하고 있습니다.
GoodRx Holdings a annoncé la nomination de Ronald E. Bruehlman à son Conseil d'administration, effective à partir du 8 novembre 2024. Bruehlman, actuellement CFO d'IQVIA, apporte 39 ans d'expérience financière dans les services de santé, l'industrie et le secteur pétrolier. Il assumera le rôle de président du Comité d'audit et de gestion des risques du Conseil, remplaçant Julie Bradley. Auparavant, Bruehlman a été CFO d'IMS Health et a occupé des postes de leadership financier senior chez United Technologies pendant 23 ans. Cette nomination vise à renforcer la stratégie financière de GoodRx et ses capacités d'évaluation des risques alors que l'entreprise se concentre sur une croissance des revenus durable et rentable.
GoodRx Holdings hat die Ernennung von Ronald E. Bruehlman in den Vorstand bekannt gegeben, die am 8. November 2024 wirksam wird. Bruehlman, der derzeit CFO von IQVIA ist, bringt 39 Jahre Erfahrung im Finanzwesen in den Bereichen Gesundheitsdienstleistungen, Industrie und Erdöl mit. Er wird den Vorsitz des Prüfungsausschusses und des Risikogremiums des Vorstands übernehmen und Julie Bradley ersetzen. Zuvor war Bruehlman CFO von IMS Health und hatte 23 Jahre lang leitende Finanzpositionen bei United Technologies inne. Die Ernennung zielt darauf ab, die Finanzstrategie und die Risikoanalysefähigkeiten von GoodRx zu stärken, während sich das Unternehmen auf nachhaltiges und profitables Umsatzwachstum konzentriert.
- Addition of seasoned healthcare finance executive with 39 years of industry experience
- Strengthening of financial oversight through new Audit and Risk Committee chairperson
- Strategic expertise in healthcare and technology sectors aligned with company growth objectives
- None.
IQVIA CFO brings 39 years of healthcare and finance expertise to GoodRx
"We are thrilled to welcome Mr. Bruehlman to the GoodRx Board. His extensive expertise leading financial strategies for public and private healthcare and technology companies is a perfect match for GoodRx as we navigate the complex healthcare market," said Trevor Bezdek, GoodRx co-founder and Chairman of the Board. "Mr. Bruehlman’s deep financial insight and strategic acumen will be critical as we continue to focus on sustainable and profitable revenue growth, aiming to enhance affordability and access to prescription medications across the country. His leadership will ensure the highest standards of financial management and strategic risk assessment as we drive forward our mission.”
Mr. Bruehlman will also serve as the chairperson of the Board’s Audit and Risk Committee, following Julie Bradley’s resignation as a member of GoodRx’s Board of Directors effective on November 8, 2024.
About GoodRx
GoodRx is the leading prescription savings platform in the
GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (“SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the anticipated contributions from Ronald E. Bruehlman in his directorship and expected benefits to the Company and our Board. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to attract and retain talent and the important factors discussed under the caption “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2023, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241028840743/en/
Investor Contact
ir@goodrx.com
Media Contact
press@goodrx.com
Source: GoodRx
FAQ
When will Ronald Bruehlman join GoodRx (GDRX) Board of Directors?
What position will Bruehlman hold on GoodRx's (GDRX) Board?
Who is Bruehlman replacing on GoodRx's (GDRX) Board?
What is Bruehlman's current role outside of GoodRx (GDRX)?
